Phase II Study of KRP-209

Phase II Study of KRP-209- A Double-Blind, Placebo-Controlled Clinical Trial to Evaluate Efficacy and Safety of KRP-209 in Patients with Subjective Tinnitus -

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222932

Enrollment

240

Registered

2015-08-06

Start date

2015-08-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subjective tinnitus

Interventions

investigational material(s) Generic name etc : KRP-209 INN of investigational material : Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Administration for In

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with a clinical diagnosis of first onset of chronic, continuous, uni- or bilateral tinnitus.

Exclusion criteria

Exclusion criteria: Patients who have tinnitus with concomitant symptoms, such as middle ear diseases(otitis media, otosclerosis, eustachian tube dysfunction, etc), fluctuant hearing impairments(Meniere's disease, acute low-tone sensorineural hearing loss, etc), retrocochlear hearing losses(acoustic neuroma), arteriovenous malformations or a glomus tumor. Clinical diagnosis of intermittent or pulsatile tinnitus.

Design outcomes

Primary

Measure	Time frame
Change from baseline in the subjective symptom score Tinnitus Questionnaire	—

Secondary

Measure	Time frame
Changes from baseline in the subjective symptom scores at the point of each evaluation. Tinnitus Questionnaire	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026